Actylis, a global manufacturer of raw materials and performance ingredients for the life sciences and speciality chemicals markets, has opened a new 30,000 sq ft cGMP facility in Eugene, OR. The multi-million dollar construction commenced in February of 2021 and was completed in September 2022, with commissioning and qualification completed at the end of January 2023.

The Eugene facility is the latest GMP manufacturing facility that Actylis has commissioned. Along with the other GMP sites in Montreal (Canada), Limerick (Ireland) and Ahmedabad (India), Actylis has a presence in 10 countries spanning three continents and offers more than 4,500 products. Actylis’ capabilities encompass the entire R&D, product development and manufacturing spectrum, including technical sales support, R&D, manufacturing and production, quality, supply chain, global sourcing, and regulatory compliance.